(Case C-495/21 Request for a preliminary ruling from the Bundesverwaltungsgericht (Germany) lodged on 12August 2021– L.GmbH v Federal Republic of Germany
Fecha: 12-Ago-2021
Request for a preliminary ruling from the Bundesverwaltungsgericht (Germany) lodged on 12August 2021– L.GmbH v Federal Republic of Germany
(Case C-495/21)
Language of the case: German
Referring court
Bundesverwaltungsgericht
Parties to the main proceedings
Appellant on a point of law: L.GmbH
Respondent in the appeal on a point of law: Federal Republic of Germany
Questions referred
Can the principal intended action of a substance be pharmacological within the meaning of Article1(2)(a) of Directive 93/42/EEC1 even if it is not based on a receptor-mediated mode of action and the substance is not absorbed by the human body but remains on and reacts with the surface of, for example, the mucosa? On what criteria should a distinction be drawn between pharmacological and non-pharmacological means, in particular physico-chemical means, in such a case?
Can a product be regarded as a substance-based medical device within the meaning of Article1(2)(a) of Directive 93/42/EEC if, according to current scientific knowledge, the mode of action of the product is open to debate and it is thus not possible to definitively determine whether the principal intended action is achieved by pharmacological or physico-chemical means?
In such a case, is the classification of the product as a medicinal product or as a medical device to be carried out on the basis of an overall assessment of its other properties and all other circumstances, or, in so far as it is intended to prevent, treat or alleviate diseases, is the product to be regarded as a medicinal product by presentation within the meaning of Article1(2)(a) of Directive 2001/83/EC,1 irrespective of whether or not a specific medicinal effect is being claimed?
Does the primacy of the regime governing medicinal products also apply in such a case in accordance with Article2(2) of Directive 2001/83/EC?